Log in

Relevant bibliographies by topics / Sulodexide

Contents

Journal articles
Book chapters
Conference papers

Academic literature on the topic 'Sulodexide'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sulodexide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Sulodexide"

1

Pompilio, Giuseppe, Davide Integlia, Joseph Raffetto, and Gualtiero Palareti. "Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis." TH Open 04, no. 02 (2020): e80-e93. http://dx.doi.org/10.1055/s-0040-1709731.

Full text

Abstract:

Abstract Objective This network meta-analysis (NMA) assesses the clinical comparative efficacy and safety of sulodexide versus direct-acting oral anticoagulants (DOACs), vitamin K antagonist (VKA), and aspirin in patients with an unprovoked venous thromboembolism (VTE). Methods We conducted a literature search in MEDLINE, Embase, and Cochrane Library using both randomized controlled trials (RCTs) and observational studies. Reduction in recurrent deep venous thrombosis (r-DVT), pulmonary embolism (PE), major bleeding (MB), clinically relevant nonmajor bleeding (CRNMB) were the primary efficacy

APA, Harvard, Vancouver, ISO, and other styles

2

Dobrowolski, Dariusz, and Olga Łach-Wojnarowicz. "Vasoprotective Effect of Sulodexide in Diabetic Retinopathy." Ophthalmology, no. 4 (December 29, 2023): 19–22. http://dx.doi.org/10.5114/oku/177689.

Full text

Abstract:

Diabetes is a group of metabolic diseases, considered a lifestyle disease. Diabetic retinopathy is the leading cause of blindness in working-age adults worldwide. Pathogenetically, due to the changed anionic charge, collagen gradually replaces glycosaminoglycans (GAG) in the basement membrane of retinal capillaries, affecting vascular permeability. Clinically, these changes cause leakage from the retinal capillaries, which leads to the development of microaneurysms and, consequently, the formation of hard effusions (HE). Sulodexide is a glycosaminoglycan containing 80% of small molecular weigh

APA, Harvard, Vancouver, ISO, and other styles

3

Yuan, Tao, Ni Yang, Wei Bi, et al. "Protective Role of Sulodexide on Renal Injury Induced by Limb Ischemia-Reperfusion." Evidence-Based Complementary and Alternative Medicine 2021 (January 30, 2021): 1–9. http://dx.doi.org/10.1155/2021/6629718.

Full text

Abstract:

Background. Though widely known as a potent antithrombin agent with protective effects on the kidney and other remote organs, it is currently ambiguous when it comes to sulodexide’s function on ischemia-reperfusion (I/R) injury. With this research, we pursued to further explore how sulodexide exerts its influence on limb I/R injury, in which deleterious effects on the kidney were what we primarily focused on. Methods. We randomized twenty-four C57BL/6 male rats into three groups, namely, sham operation group (control group), I/R group, and sulodexide pretreatment group. Hematoxylin and eosin s

APA, Harvard, Vancouver, ISO, and other styles

4

Morozov, A. M., A. E. Avanesyan, A. A. Boltik, and A. N. Sergeev. "Possibilities of sulodexide use in clinical practice." Meditsinskiy sovet = Medical Council, no. 6 (May 12, 2023): 289–98. http://dx.doi.org/10.21518/ms2022-050.

Full text

Abstract:

Introduction. Sulodexide is a polymer, the structure of which includes unbranched polysaccharide chains formed by repeating a particular disaccharide unit. This drug was isolated from the endothelium of the pig, and it appeared on the pharmaceutical market in 1974. Sulodexide contains ≈ 80% heparan sulfate (also known as fast-acting heparin) and 20% dermatan sulfate. This drug is produced from the more sulfated waste heparinoids. During production, heparin is chemically decomposed and transformed into the clinical drug Sulodexide. Aim. To estimate the possibilities and prospects of using the d

APA, Harvard, Vancouver, ISO, and other styles

5

Zhao, Qing, Jianyong Yin, Zeyuan Lu, et al. "Sulodexide Protects Contrast-Induced Nephropathy in Sprague-Dawley Rats." Cellular Physiology and Biochemistry 40, no. 3-4 (2016): 621–32. http://dx.doi.org/10.1159/000452575.

Full text

Abstract:

Background: Sulodexide is a powerful antithrombin agent with reno-protective property. However, whether it has beneficial effects on Contrast-Induced Nephropathy (CIN) remained elusive. In the current study, we evaluated the therapeutic effects of Sulodexide on CIN and investigated the potential mechanisms. Methods: CIN model was induced by intravenous injection of indomethacin, followed by Ioversol and L-NAME. Sprague-Dawley rats were divided into 4 groups: control group, CIN group, CIN+vehicle group (CIN rats pretreated with vehicle) and CIN+ Sulodexide (CIN rats pretreated with Sulodexide).

APA, Harvard, Vancouver, ISO, and other styles

6

Gonzalez-Ochoa, Alejandro. "Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled Trial." Blood 138, Supplement 1 (2021): 667. http://dx.doi.org/10.1182/blood-2021-151814.

Full text

Abstract:

Abstract Background: SARS-CoV-2 can induce several vascular endothelial-dependent systemic complications and treatment targeting endothelial cells has been suggested. Sulodexide is a heparin and glycosaminoglycan compound that has pleiotropic properties within the vascular endothelium that can prove beneficial in COVID-19 patients. Aims: We aimed to evaluate the effect of sulodexide when used in the early clinical stages of COVID-19. Methods: In an outpatient setting, we conducted a randomized placebo-controlled trial. Key inclusion criteria were patients within three days of COVID-19 clinical

APA, Harvard, Vancouver, ISO, and other styles

7

Scondotto, Gaetano, Giancarlo Agnelli, Daniele Aloisi, Ernesto Palazzini, Villiam Zamboni, and Sergio Coccheri. "Randomised, Double Blind, Multicentre, Placebo Controlled Study of Sulodexide in the Treatment of Venous Leg Ulcers." Thrombosis and Haemostasis 87, no. 06 (2002): 947–52. http://dx.doi.org/10.1055/s-0037-1613116.

Full text

Abstract:

SummarySulodexide, a highly purified glycosaminoglycan, was investigated for treatment of venous leg ulcers. Patients (n = 235) undergoing local treatment including wound care and compression bandaging, were randomised to receive either sulodexide or matching placebo for three months. Primary study endpoint was complete ulcer healing after 2 months; secondary endpoints were ulcer healing at 3 months and the time-course changes of ulcer areas.The proportion of patients with complete ulcer healing was higher with sulodexide at 2 months (p = 0.018) and 3 months. The “number needed to treat” to ob

APA, Harvard, Vancouver, ISO, and other styles

8

Reyes, Eugenio B., Paula Victoria Catherine Y. Cheng-Bromeo, and Nigel Jeronimo C. Santos. "The Effect of Sulodexide on the Incidence of Cardiovascular Outcomes in Patients With Vascular Disorders." Philippine Journal of Cardiology 53, no. 1 (2025): 87–97. https://doi.org/10.69944/pjc.06659058d5.

Full text

Abstract:

Background and Objectives: Among patients with macrovascular and microvascular disease, we investigated the association between sulodexide and cardiovascular (CV) outcomes and adverse events. Methods: We conducted a meta-analysis of randomized control trials (RCTs) reporting CV outcomes and adverse events in patients with vascular disease receiving sulodexide for any indication versus control. The following outcomes were investigated: any CV event, myocardial infarction, CV death, bleeding events and gastrointestinal symptoms. Results: Twelve studies with a total of 8,436 patients were include

APA, Harvard, Vancouver, ISO, and other styles

9

Satirapoj, Bancha, Wisit Kaewput, Ouppatham Supasyndh, and Prajej Ruangkanchanasetr. "Effect of Sulodexide on Urinary Biomarkers of Kidney Injury in Normoalbuminuric Type 2 Diabetes: A Randomized Controlled Trial." Journal of Diabetes Research 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/172038.

Full text

Abstract:

Glycosaminoglycans or sulodexide has shown benefits in early experimental diabetic nephropathy (DN) models, but its efficacy in patients with early stage of DN is unknown.Methods. Twenty patients were randomly assigned to the placebo group and another 20 patients were randomly assigned to receive sulodexide 100 mg/day for 14 weeks. Primary outcome was a change of urinary TGF-beta1, albuminuria, and glomerular filtration rate (GFR). All patients had stable metabolic profiles for at least 90 days before randomization.Results. Urinary TGF-beta1 increased significantly in the placebo group but did

APA, Harvard, Vancouver, ISO, and other styles

10

Gonzalez-Ochoa, Alejandro J., Joseph D. Raffetto, Ana G. Hernández, et al. "Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial." Thrombosis and Haemostasis 121, no. 07 (2021): 944–54. http://dx.doi.org/10.1055/a-1414-5216.

Full text

Abstract:

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce several vascular endothelial-dependent systemic complications, and sulodexide has pleiotropic actions on the vascular endothelium, which may prove beneficial. We aimed to assess the effect of sulodexide when used within 3 days of coronavirus disease 2019 (COVID-19) clinical onset. We conducted a randomized placebo-controlled outpatient trial. To be included, patients must have been at high risk for severe clinical progression. Participants received sulodexide (oral 1,000 LRU/d) or placebo for 21 days. The primary e

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Sulodexide"

1

Dou, Huaiqian, Aiqin Song, Shaoyou Jia, and Lijuan Zhang. "Heparinoids Danaparoid and Sulodexide as clinically used drugs." In Progress in Molecular Biology and Translational Science. Elsevier, 2019. http://dx.doi.org/10.1016/bs.pmbts.2019.02.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Sulodexide"

1

Dharavath, B., E. Bontekoe, A. Kouta, O. Iqbal, D. Hoppenstaedt, and J. Fareed. "Sulodexide as a Parenteral Anticoagulant. A Substitute for Unfractionated Heparin." In 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1728153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dharavath, B., O. Iqbal, D. Hoppensteadt, E. Bontekoe, and J. Fareed. "Whole blood anticoagulant effects of Sulodexide as measured by activated clotting time and their neutralization by Protamine sulfate." In 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1728154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!